- Home
- TGS vs ORKA Comparison
TGS vs ORKA Comparison
Compare TGS & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TGS | ORKA |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | Argentina | United States |
| Employees | N/A | 68 |
| Industry | Natural Gas Distribution | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.5B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | TGS | ORKA |
|---|---|---|
| Price | $30.52 | $91.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $40.00 | ★ $92.50 |
| AVG Volume (30 Days) | 208.2K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.13 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.74 | $12.84 |
| 52 Week High | $36.35 | $97.78 |
Technical Indicators
Market Signals| Indicator | TGS | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 60.86 |
| Support Level | $30.08 | $80.94 |
| Resistance Level | $31.92 | $97.02 |
| Average True Range (ATR) | 0.99 | 4.65 |
| MACD | 0.08 | -0.35 |
| Stochastic Oscillator | 48.27 | 74.12 |
Price Performance
Historical ComparisonAbout TGS Transportadora de Gas del Sur SA TGS
Transportadora de Gas del Sur SA is a natural gas transporter in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, and Liquids Production and Commercialization. It generates maximum revenue from the Natural Gas Transportation segment. Geographically, it derives the majority of its revenue from Argentina.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.